PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma
about
Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcomaPazopanib in sarcomas: expanding the PALETTESynovial sarcoma: recent discoveries as a roadmap to new avenues for therapyCixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialThe N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanismTargeting the PDGF signaling pathway in tumor treatmentEmerging therapeutic targets for synovial sarcoma.Ciliary transport regulates PDGF-AA/αα signaling via elevated mammalian target of rapamycin signaling and diminished PP2A activity.MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymomaNext generation sequencing in synovial sarcoma reveals novel gene mutations.Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature.Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Targeted therapy for soft tissue sarcomas in adolescents and young adults.Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.Novel therapeutic approaches in chondrosarcoma.Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein.Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy.Olaratumab for soft tissue sarcoma.Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis.Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.Short-term hypoxia improves early cardiac progenitor cell function in vitro.Sodium selenite induces apoptosis and inhibits autophagy in human synovial sarcoma cell line SW982 in vitro.
P2860
Q21245750-9AB5E2E3-4DC3-4242-8ADC-CEB3CAEACBA3Q26825050-77B01B1D-7BAE-4941-B7EC-3A86870A3967Q28087134-74472C8E-D7B2-4D7B-8430-D23F0CE98D13Q33406371-708830F2-04D4-4A30-840C-BD616A289835Q33913982-858D54BD-2347-444F-8EBE-09875B43CDA8Q34393461-C4E3DE12-E32D-4ADC-8FBA-00CE5A410982Q34660607-E37644AC-53EB-4EED-AABC-C2B582CE7FBAQ34960781-B5F1A2E3-97BF-4541-9B1A-B9A23F365BEDQ35096201-2C4B42C0-3482-49FC-B120-A2937A06D5CFQ35583984-63A4200A-1141-4A4A-B2DF-3601BB88FC44Q36544186-4B458FB7-C97C-4134-B168-45A544141EF0Q36924325-18FA2BA4-530F-4031-AFA1-1728290161F6Q36926098-9FA4EDCB-6C02-4BC5-AEDA-C593C4DAD5A1Q37742014-8D4D7C48-3D29-494D-90F5-49082973EAF7Q38543837-20A70DBE-832F-4131-BF0B-95030D064A9FQ38569799-0B02B4C2-C861-482D-997A-6786F9C5CF6AQ38764510-B004F0CA-CAFF-4E8E-94FF-5DD76D7ABD7AQ39216584-91F01531-D5CD-403D-9478-BC81A7E8BA34Q39233440-62E179ED-187F-4CAB-900F-E58A025F288DQ39425301-150CF59D-BA60-445C-8855-90F1497C3599Q39996613-F95F2AA7-BBB8-43BE-AD3D-6C0B5D07505DQ47756210-4B881803-4566-4417-9529-4F2A3B5201BCQ47994466-B03B7E70-67C8-4D7D-83BC-48262E9576AEQ52726988-7D94D28A-8E29-4EEB-AEF7-F408F6B40E94Q54943194-315FA318-8700-4CC1-9B70-03509D05DACC
P2860
PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
PDGF receptor alpha is an alte ...... ed therapy of synovial sarcoma
@ast
PDGF receptor alpha is an alte ...... ed therapy of synovial sarcoma
@en
type
label
PDGF receptor alpha is an alte ...... ed therapy of synovial sarcoma
@ast
PDGF receptor alpha is an alte ...... ed therapy of synovial sarcoma
@en
prefLabel
PDGF receptor alpha is an alte ...... ed therapy of synovial sarcoma
@ast
PDGF receptor alpha is an alte ...... ed therapy of synovial sarcoma
@en
P2093
P2860
P1433
P1476
PDGF receptor alpha is an alte ...... ed therapy of synovial sarcoma
@en
P2093
Cristina R Antonescu
Gary K Schwartz
Marick Laé
Shyamprasad Deraje Vasudeva
Tsuyoshi Saito
Violetta Barbashina
P2860
P304
P356
10.1158/0008-5472.CAN-12-1319
P407
P50
P577
2012-07-10T00:00:00Z